恒瑞医药(600276) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥5,717,263,637.41, a decrease of 17.16% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥1,054,058,173.56, down 31.54% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,042,496,132.55, a decrease of 30.59% compared to the previous year[4]. - The basic earnings per share for the quarter was ¥0.17, reflecting a decline of 29.17% year-on-year[5]. - Total revenue for the first three quarters of 2022 was ¥15,945,305,398.30, a decrease of 21.1% compared to ¥20,198,968,493.15 in the same period of 2021[14]. - Net profit for the first three quarters of 2022 was ¥3,096,046,599.46, down 26.1% from ¥4,191,900,765.96 in 2021[15]. - Operating profit for the first three quarters of 2022 was ¥3,651,832,331.55, a decline of 28.0% from ¥5,073,046,461.30 in 2021[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥2,187,574,452.30, down 37.47% compared to the same period last year[5]. - The net cash flow from operating activities for Q3 2022 was approximately $2.19 billion, a decrease of 37.5% compared to $3.50 billion in Q3 2021[17]. - The total cash outflow from operating activities was approximately $13.60 billion, a decrease of 17.0% from $16.38 billion in Q3 2021[17]. - Cash paid for purchasing goods and services was approximately $689.1 million, a decrease from $756.9 million in the same quarter last year[17]. - Cash paid to employees was approximately $4.54 billion, down from $5.18 billion in Q3 2021, indicating a reduction of 12.6%[17]. Assets and Liabilities - The total assets at the end of the quarter were ¥40,175,041,688.79, an increase of 2.31% compared to the end of the previous year[5]. - Total assets as of September 30, 2022, were ¥40,175,041,688.79, an increase of 2.3% from ¥39,266,221,700.14 at the end of 2021[13]. - Total liabilities as of September 30, 2022, were ¥2,865,322,043.11, a decrease of 22.4% from ¥3,694,413,772.82 at the end of 2021[13]. - Current assets totaled ¥29,615,954,099.79 as of September 30, 2022, a slight decrease from ¥30,187,749,035.96 at the end of 2021[12]. Investments and Equity - The total equity attributable to shareholders was ¥36,753,047,980.85, up 5.00% from the previous year[5]. - The company reported a significant increase in long-term equity investments, rising to ¥492,826,121.92 from ¥192,826,121.92 in the previous year[12]. Research and Development - Research and development expenses for the first three quarters of 2022 were ¥3,497,538,601.73, down from ¥4,141,956,943.25 in 2021, indicating a reduction of 15.5%[14]. Cash and Tax - The company’s cash and cash equivalents increased to ¥16,000,041,927.04 as of September 30, 2022, compared to ¥13,630,819,615.77 at the end of 2021, reflecting a growth of 17.5%[12]. - The company received tax refunds amounting to approximately $212.2 million in Q3 2022, compared to $41.2 million in Q3 2021[17]. Investment Activities - Total cash inflow from investment activities was approximately $8.79 billion, down from $9.85 billion in the same quarter last year, representing a decline of 10.8%[17]. - The net cash flow from investment activities increased significantly to approximately $1.55 billion, compared to $551.4 million in Q3 2021[17]. Financing Activities - Cash inflow from financing activities totaled approximately $587.5 million, a substantial increase from $316 million in Q3 2021[17]. - The net cash flow from financing activities was negative at approximately -$1.56 billion, worsening from -$759.4 million in the previous year[17].